Company / Cash & Equivalents
BIOCRYST PHARMACEUTICALS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$89.7M
FY2025
5-year range
$89.7M / $504.4M
FY2021-FY2025
Trend
-14.3%
vs FY2024
Sector context
#147 of 207
Health Care
What the data says
At $90M, BIOCRYST PHARMACEUTICALS INC's cash & equivalents ranks #147 of 207 in the Health Care sector. Cash & Equivalents has declined for 4 consecutive years, from $504M in FY2021 to $90M in FY2025.
Based on SEC 10-K filings.
$90M in FY2025 with a 5-year CAGR of -19.9%.
Declined from $111M to $90M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -33.5%
- 5-Year CAGR
- -19.9%
- 10-Year CAGR
- -
Sector benchmark
#147 of 207 in Health CareTop 71% of 207This company $89.7M Sector average $669.5M
▼
-86.6% below sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -19.9%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 14.3% year-over-year.
- Ranks #147 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.7M | -14.3% |
| FY2024 | $104.7M | -5.4% |
| FY2023 | $110.6M | -63.7% |
| FY2022 | $304.8M | -39.6% |
| FY2021 | $504.4M | +85.4% |
| FY2020 | $272.1M | +138.3% |
| FY2019 | $114.2M | +327.1% |
| FY2018 | $26.7M | -46.8% |
| FY2017 | $50.3M | +127.5% |
| FY2016 | $22.1M | -23.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026